New Therapeutics for Unmet Global Needs

Algernon Pharmaceuticals is a clinical stage, Canadian drug development and repurposing company investigating multiple drugs for unmet global medical needs. Our lead candidate Repirinast, for the treatment of kidney fibrosis, is being advanced through an innovative drug repurposing model, while a second lead program involves the new application of a naturally occurring psychedelic compound for the treatment of stroke and traumatic brain injuries (TBI). This latter initiative is being advanced through our subsidiary operation Algernon NeuroScience.

Featured Video

Algernon Pharmaceuticals CEO Christopher J. Moreau discusses the Company's unique drug development and repurposing strategy and its lead DMT research program for stroke and traumatic brain injury (TBI).

repurpose section

Risk Reduced, Capital-Efficient Drug Development

Drug repurposing offers several benefits over traditional drug development: shorter research periods, longer active patent life, and lower risk of safety issues during human trials. One of our key strategies is to begin our investigation of compounds by conducting off-label Phase 1 & 2 trials in countries like Australia, where our clinical investigators need not repeat preclinical work already conducted in the drug’s country of origin.

Key Advantages

  • We target a billion-dollar market: global diseases
  • We work to move compounds directly into Phase 1 & 2 clinical trials
  • We repurpose safe, already approved drugs, which have a much lower risk of failure than developing new chemical entities
  • We have a U.S. FDA and international clinical trial experienced management team and globally recognized medical and scientific advisors
  • Our business model is highly capital efficient

New Chemical Entity (NCE) Development Pathway and Failure Rates

Repurposing existing, safe, small molecules to treat different disease applications requires lower capital investment, has a reduced risk of failure due to toxicity or safety issues, and usually features shorter development periods because the compounds can be moved into clinical trials more quickly than new chemical entities.

The below chart shows the challenges associated with developing a new chemical entity from scratch and moving it through all the required stages to market.

The development pathway and failure rates challenges associated with developing a new chemical entity from pre-clinical phase to market

A Fast-Tracked Pipeline for New Therapies

Our strategy is to fast-track our lead candidates directly into Phase 1 & 2 clinical trials as efficiently and safely as possible. We are currently investigating new potential therapeutic treatments for chronic kidney disease, as well as stroke and traumatic brain injury (TBI).

SEE OUR PIPELINE

Our Corporate Fact Sheet

Click here for a summary of Algernon’s strategy and business milestones.

Download

A Passion for Discovery and Value

Some of the best and brightest leaders in the industry are on the Algernon Pharmaceuticals team.

Our Management Team Our Board of Directors Our Medical & Scientific Advisors